Not Yet RecruitingPhase 2ACTRN12614000522617

Assessment of three e-cigarette nicotine blends, when used by current smokers.

A Four-Way Crossover Study Comparing Nicotine Pharmacokinetics and Exhaled Carbon Monoxide Levels of a Traditional Tobacco Cigarette and Three Nicotine-Based eLiquid Blends Delivered via e-Cigarette, Following Single Use in Healthy Male Smokers.


Sponsor

Ploom

Enrollment

24 participants

Start Date

May 19, 2014

Study Type

Interventional

Conditions

Summary

Measuring nicotine levels in blood following smoking tobacco and e-cigarettes


Eligibility

Sex: MalesMin Age: 18 YearssMax Age: 45 Yearss

Inclusion Criteria1

  • Smoke at least 5 cigarettes per day.

Exclusion Criteria1

  • Impaired lung function

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

This study compares three commercially available eliquid blends with a standard cigarette. For each of the 3 blends, nicotine concentration is the same, 2%(w/w), 34uL = 0.8 mg nicotine. Typical e-

This study compares three commercially available eliquid blends with a standard cigarette. For each of the 3 blends, nicotine concentration is the same, 2%(w/w), 34uL = 0.8 mg nicotine. Typical e-liquid use is 17-51 uL over 10 inhalations (20 - 60 mg delta weight observed when weighing the e-cig before and after use). This represents between 0.4 - 1.2 mg nicotine per series of 10 inhalations. In particular, researchers want to know: How much nicotine gets into the blood with each product? How quickly does nicotine reach maximum levels in the blood with each product? How much does breath CO increase after using each product? Each participant will smoke one standard tobacco cigarette and 3 e-cigarettes in a randomised order 90 minutes apart


Locations(1)

New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12614000522617


Related Trials